Last $3.42 USD
Change Today -0.18 / -5.00%
Volume 142.3K
OCLS On Other Exchanges
Symbol
Exchange
OCLS is not on other exchanges.
As of 8:10 PM 04/15/14 All times are local (Market data is delayed by at least 15 minutes).

oculus innovative sciences i (OCLS) Snapshot

Open
$3.65
Previous Close
$3.60
Day High
$3.65
Day Low
$3.31
52 Week High
12/4/13 - $7.21
52 Week Low
11/21/13 - $2.20
Market Cap
26.3M
Average Volume 10 Days
107.5K
EPS TTM
$-0.95
Shares Outstanding
7.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OCULUS INNOVATIVE SCIENCES I (OCLS)

oculus innovative sciences i (OCLS) Related Bloomberg News

View More Bloomberg News

oculus innovative sciences i (OCLS) Related Businessweek News

No Related Businessweek News Found

oculus innovative sciences i (OCLS) Details

Oculus Innovative Sciences, Inc. designs, produces, and markets prescription and non-prescription products based on its Microcyn platform technology for the dermatology, surgical, advanced wound and tissue care, and animal healthcare markets in the United States, Mexico, Europe, and internationally. The Microcyn platform technology is based on electrically charged oxychlorine small molecules that target a range of organisms that cause disease, which include viruses, fungi, spores, and antibiotic-resistant strains of bacteria, such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus, as well as Clostridium difficile, a highly contagious bacteria spread by human contact. It offers Microcyn-based human advanced wound and skin care products as prescription and over-the-counter products; and Microcyn technology-based animal healthcare products under the Vetericyn brand. The company also offers Glucorein Green Tea with chlorogenic acid, a medical food for the dietary management of glucose levels in pre-diabetics and type 2 diabetics. Its Microcyn has received seven 510(k) clearances for use as a medical device in wound care management, including for acute and chronic wounds, and in dermatology applications. In addition, the company provides consulting and laboratory services to medical companies that design and manufacture biomedical devices and drugs. It sells its products to hospitals, physicians, nurses, and other healthcare practitioners, as well as to dermatologists. Oculus sells its products directly, as well as through contract sales organization and distributors. The company was formerly known as Micromed Laboratories, Inc. and changed its name to Oculus Innovative Sciences, Inc. in August 2001. Oculus Innovative Sciences, Inc. was incorporated in 1999 and is based in Petaluma, California.

41 Employees
Last Reported Date: 06/25/13
Founded in 1999

oculus innovative sciences i (OCLS) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $300.0K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $250.0K
Executive Vice President of International Ope...
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2013.

oculus innovative sciences i (OCLS) Key Developments

Oculus Innovative Sciences, Inc. Announces Board Changes

Oculus Innovative Sciences, Inc. announced that effective March 26, 2014, Hojabr Alimi and Richard Conley each tendered his resignation as a member of board of directors and his respective committee appointments. On March 26, 2014, board of directors appointed Sharon Barbari as a director of company. Ms. Barbari was also appointed as chairperson of Audit Committee, and as a member of Nominating and Corporate Governance Committee. Ms. Barbari has served as Executive Vice President - Finance and Chief Financial Officer, of Cytokinetics Inc. since July 2009. The independent members of board have appointed Jerry McLaughlin to serve as lead independent director of board of directors, effective March 26, 2014. Mr. McLaughlin has served as a member of board of Directors since March 2013.

Oculus Innovative Sciences, Inc. Appoints Sharon Barbari to its Board of Directors, Effective March 26, 2014

Oculus Innovative Sciences, Inc. announced the appointment of Sharon Barbari to its board of directors, effective March 26, 2014. Ms. Barbari currently serves as executive vice president and CFO for Cytokinetics, Inc.

Oculus Innovative Sciences, Inc. Appoints Russell Harrison to its Board of Directors

Oculus Innovative Sciences, Inc. announced the appointment of Russell ("Russ") Harrison to its board of directors, effective February 26, 2014. Harrison is the founding principal of The Leadership Group. He began his business career with then-fledgling Electronic Data Systems. In the years after, Russ served as senior vice president at Bank of America, as chief information officer at McKesson and at SITA Telecommunications Holdings, and as founding president of AMR Information Systems, an American Airlines information technology subsidiary.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OCLS:US $3.42 USD -0.18

OCLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,121 JPY +24.00
Integra LifeSciences Holdings Corp $44.97 USD +0.63
Novartis AG SFr.74.45 CHF +0.90
Smith & Nephew PLC 860.00 GBp -11.50
View Industry Companies
 

Industry Analysis

OCLS

Industry Average

Valuation OCLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.7x
Price/Book 7.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.6x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCULUS INNOVATIVE SCIENCES I, please visit www.oculusis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.